Understanding the heterogeneity of pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, treatment-resistant cancer characterized by extensive inter- and intra-tumoral heterogeneity. Although over 95 % of cases harbor KRAS mutations and commonly altered tumor suppressors like TP53, SMAD4, and CDKN2A, these genetic changes a...

Full description

Bibliographic Details
Published in:	Translational Oncology
Main Authors:	Juan Iovanna, Nicolas Fraunhoffer, Raul Urrutia, Nelson Dusetti
Format:	Article
Language:	English
Published:	Elsevier 2025-10-01
Subjects:	PDAC Tumor heterogeneity Metastases Tumor progression Tumor microenvironment Epigenetics
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523325002104

Similar Items

Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome
by: Natalia Anahi Juiz, et al.
Published: (2019-04-01)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
by: Jingchang Zhang, et al.
Published: (2022-07-01)

Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma
by: Dimitrios Papakonstantinou, et al.
Published: (2025-01-01)

Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies
by: Songyu Guo, et al.
Published: (2024-03-01)

Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma
by: Remya P. G. Ramesh, et al.
Published: (2025-03-01)

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma
by: Analia Meilerman Abuelafia, et al.
Published: (2025-07-01)

CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy
by: Andrea Resovi, et al.
Published: (2020-04-01)

Mechanistic insights and therapeutic strategies for targeting autophagy in pancreatic ductal adenocarcinoma
by: Federica Michetti, et al.
Published: (2025-04-01)

Abnormalities in T cell subsets in the circulating immunity and tumor microenvironment in patients with pancreatic ductal adenocarcinoma
by: SU Bingwei, SHEN Baiyong
Published: (2025-03-01)

The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
by: Sona Ciernikova, et al.
Published: (2020-12-01)

Tumor Microenvironment Role in Pancreatic Cancer Stem Cells
by: Aaron Galindo-Vega, et al.
Published: (2023-06-01)

Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibrogenesis
by: Rasmus S. Pedersen, et al.
Published: (2022-09-01)

High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma
by: Neel I. Nissen, et al.
Published: (2023-03-01)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
by: Robyn D. Gartrell, et al.
Published: (2022-12-01)

Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing
by: Lisa Knoll, et al.
Published: (2024-07-01)

Pseudopterosin and <i>O</i>-Methyltylophorinidine Suppress Cell Growth in a 3D Spheroid Co-Culture Model of Pancreatic Ductal Adenocarcinoma
by: Bailu Xie, et al.
Published: (2020-06-01)

Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells
by: Xinbo Wang, et al.
Published: (2022-06-01)

Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3
by: Rosalinda Trovato, et al.
Published: (2019-09-01)

Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
by: Conner Hartupee, et al.
Published: (2024-02-01)

Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer
by: Padma Kadiyala, et al.
Published: (2022-05-01)

Spatial transcriptomics reveals the heterogeneity and FGG+CRP+ inflammatory cancer-associated fibroblasts replace islets in pancreatic ductal adenocarcinoma
by: Zhangyong Ren, et al.
Published: (2023-04-01)

Syndecans and Pancreatic Ductal Adenocarcinoma
by: Nausika Betriu, et al.
Published: (2021-02-01)

Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review
by: Antonella Argentiero, et al.
Published: (2019-10-01)

Integrating Multiple Methods to Validate Key Genes Driving the Progression of Breast Ductal Carcinoma In Situ
by: Minjie Zhong, et al.
Published: (2025-10-01)

An insight to PDAC tumor heterogeneity across pancreatic subregions using computed tomography images
by: Sehrish Javed, et al.
Published: (2024-11-01)

Intratumoral microbiota of pancreatic ductal adenocarcinoma impact patient prognosis by influencing tumor microenvironment
by: Jingze Leng, et al.
Published: (2024-09-01)

The recent advances of cancer associated fibroblasts in cancer progression and therapy
by: Chenxi Wu, et al.
Published: (2022-09-01)

Emerging understanding of multiscale tumor heterogeneity
by: Michael J Gerdes, et al.
Published: (2014-12-01)

Tumor heterogeneity: preclinical models, emerging technologies, and future applications
by: Marco Proietto, et al.
Published: (2023-04-01)

The tumor–stroma ratio and the immune microenvironment improve the prognostic prediction of pancreatic ductal adenocarcinoma
by: Mei Lu, et al.
Published: (2023-07-01)

Editorial: Genetic and cellular heterogeneity in tumors
by: Zishan Wang, et al.
Published: (2024-12-01)

Immunohistochemical Evaluation of the Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma
by: Gelu Mihai Breaza, et al.
Published: (2025-03-01)

Impact of Tumor Localization on Early Recurrence After Curative Resection in Pancreatic Ductal Adenocarcinoma
by: Eda Caliskan Yildirim, et al.
Published: (2025-10-01)

Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
by: Qian Zhu, et al.
Published: (2022-04-01)

Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cellsResearch in context
by: Nicolas A. Fraunhoffer, et al.
Published: (2023-06-01)

Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles
by: Hassan A. Ali, et al.
Published: (2024-10-01)

Proteomics Approach Highlights Early Changes in Human Fibroblasts-Pancreatic Ductal Adenocarcinoma Cells Crosstalk
by: Verena Damiani, et al.
Published: (2022-03-01)

Expression levels of β1, β3 integrins and MMP2 and features of morphological heterogeneity of pancreatic ductal adenocarcinoma associated with distant metastasis
by: Yu. Yu. Rakina, et al.
Published: (2023-05-01)

An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
by: Tianpeng Zhang, et al.
Published: (2023-12-01)

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
by: Etienne D. Foucher, et al.
Published: (2018-05-01)